Source / episode info
- **Episode:**6
- **Title:**Divine Intervention Episode 6 – 20 in about 20 minutes (Pharmacology Cases).
- **Published:**2018-03-15
- Source:Episode page
One-liner
This episode is a comprehensive pharmacology review covering drug toxicities and indications for various infections and malignancies, including the use of H2 antagonists (Cimetidine), iron chelators (Deferoxamine), tyrosine kinase inhibitors (Imatinib), anti-fungals (Amphotericin B/Flucytosine), and critical contraindications like Chloramphenicol in UGT deficiency.
High-yield summary
- PNH Management: PNH is caused by a PIGA mutation -> loss of GPI-anchored complement regulatory proteins CD55/CD59 -> complement-mediated intravascular hemolysis. Treatment requires C5 blockade using Eculizumab; because terminal complement blockade increases Neisseria risk, patients require meningococcal vaccination/prophylaxis.
- Malignancy Drug Classes: Anti-cancer agents often target specific pathways: Anthracyclines require iron chelation (Dexrazoxane) to prevent cardiotoxicity; CML is treated with TKIs like Imatinib (targeting BCR-ABL).
- Infectious Disease Pearls: CMV requires Ganciclovir/Valganciclovir (DNA polymerase inhibitors); TB requires RIPE (Rifampin, Isoniazid, Pyrazinamide, Ethambutol); and Pneumocystis jirovecii pneumonia prophylaxis uses TMP-SMX.
- Drug Toxicity/Contraindications: Be wary of drug side effects: Aminoglycosides cause neuromuscular blockade; Metronidazole causes a disulfiram-like reaction; Chloramphenicol is contraindicated in neonates with UGT deficiency (Gray baby syndrome) and patients with Crigler-Najjar Syndrome.
- Immunology/Oncology Links: Anti-integrin antibodies (Natalizumab) carry the risk of PML due to JC virus reactivation, linking immunology to CNS pathology.
Learning objectives
- Identify and manage drug toxicities associated with anti-cancer therapies (e.g., anthracyclines, TKIs).
- Differentiate between various types of acquired coagulopathies/hemolytic anemias requiring complement pathway modulation (PNH).
- Recognize the clinical presentation and appropriate prophylaxis for opportunistic infections in immunocompromised patients (CMV, TB, Toxoplasma, PCP).
- Understand the mechanism and contraindications of key antibiotics and antifungals (e.g., Amphotericin B, Chloramphenicol).
- Correlate genetic mutations with cancer progression (APC -> KRAS -> p53) and drug failure.
Board exam buzzwords